Umifenovir 50 mg 20 capsules

Prevention and treatment of influenza A and B, other acute respiratory viral infections (ARVI) in adults and children from 3 years old (for the 50 mg capsule form), from 6 years old (for the 100 mg capsule form).
Comprehensive therapy for recurrent herpes infection.
Prevention of postoperative infectious complications.

Orally, before meals.
Single dose: children aged 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg (1 capsule of 100 mg or 2 capsules of 50 mg), over 12 years and adults - 200 mg (2 capsules of 100 mg or 4 capsules of 50 mg)
For nonspecific prevention and treatment of influenza and other acute respiratory viral infections (ARVI) in children and adults:
Nonspecific prevention:
During the influenza epidemic and other ARVI: children aged 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years and adults - 200 mg twice a week for 3 weeks.
Upon direct contact with individuals infected with influenza and other ARVI: children aged 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years and adults - 200 mg once daily for 10-14 days.
Treatment of influenza and other ARVI: children aged 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years and adults - 200 mg 4 times a day (every 6 hours) for 5 days.
In combination therapy for recurrent herpes infection: children aged 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years and adults - 200 mg 4 times a day (every 6 hours) for 5-7 days, then a single dose 2 times a week for 4 weeks.
Prevention of postoperative infectious complications: children aged 3 to 6 years - 50 mg, from 6 to 12 years - 100 mg, over 12 years and adults - 200 mg 2 days before surgery, then on days 2 and 5 after surgery.
The medication should be started at the onset of the first symptoms of influenza and other ARVI, preferably no later than 3 days from the onset of the illness. If symptoms persist for three days during the treatment of influenza and other ARVI, including high fever (over 38 °C), it is necessary to consult a doctor to assess the appropriateness of continuing the medication.
Use the medication only according to the indications, method of administration, and dosages specified in the instructions.

Composition per 1 capsule:
Active ingredient: umifenovir hydrochloride monohydrate - 51.75 mg, calculated as umifenovir hydrochloride - 50.00 mg.
Excipients: microcrystalline cellulose - 31.85 mg; potato starch - 16.50 mg; povidone K25 - 5.50 mg; sodium croscarmellose - 2.20 mg; colloidal silicon dioxide - 1.10 mg; magnesium stearate - 1.10 mg.
Capsule shell composition: quinoline yellow dye - 0.7500%; sunset yellow dye - 0.0059%; titanium dioxide - 2.0000%; gelatin - up to 100%.
Capsule cap composition: quinoline yellow dye - 0.7500%; sunset yellow dye - 0.0059%; titanium dioxide - 2.0000%; gelatin - up to 100%.

Hard gelatin capsules No. 2. The body and cap are yellow, opaque. The contents of the capsules: a mixture of powder and granules ranging from white to white with a greenish-yellow or beige tint. Compaction of the capsule contents into lumps that disintegrate upon pressure is permissible.

Increased sensitivity to umifenovir or any component of the drug; age under 3 years (for the 50 mg dosage form); age under 6 years (for the 100 mg dosage form); first trimester of pregnancy; breastfeeding.
With caution:
Second and third trimesters of pregnancy
Pregnancy and lactation:
Animal studies have not revealed harmful effects on the course of pregnancy, embryonic and fetal development, labor, and postnatal development.
The use of the drug in the first trimester of pregnancy is contraindicated.
In the second and third trimesters of pregnancy, the drug may be used only for the treatment and prevention of influenza and only if the expected benefit to the mother outweighs the potential risk to the fetus. The benefit/risk ratio is determined by the attending physician.
It is unknown whether umifenovir passes into breast milk in lactating women. If the drug is necessary, breastfeeding should be discontinued.

It is necessary to adhere to the recommended dosage regimen and duration of the medication as stated in the instructions.
In case of a missed dose, it should be taken as soon as possible, and the course of treatment should be continued according to the established regimen.
If symptoms of the disease, including high fever (38°C and above), persist for three days after using the medication for the treatment of influenza and other acute respiratory viral infections (ARVI), it is necessary to consult a doctor to assess the appropriateness of continuing the medication.
Effect on the ability to drive vehicles and operate machinery:
It does not exhibit central neurotropic activity and can be used in medical practice by individuals in various professions, including those requiring increased attention and coordination of movements (drivers, operators, etc.).

Umifenovir is classified as a low-toxicity medication and is generally well tolerated. Side effects occur rarely, usually are mild or moderate in severity, and are transient in nature.
The frequency of adverse drug reactions is defined according to the WHO classification: very common (frequency greater than 1/10), common (frequency of at least 1/100 but less than 1/10), uncommon (frequency of at least 1/1000 but less than 1/100), rare (frequency of at least 1/10000 but less than 1/1000), very rare (frequency less than 1/10000), frequency unknown (cannot be established from the available data).
Immune system disorders: rare - allergic reactions.
If any of the side effects listed in the instructions worsen, or if you notice any other side effects not listed in the instructions, inform your doctor.

Data on drug overdose is not available.

No negative effects have been noted when prescribed with other medications.
Special clinical studies dedicated to the interaction of umifenovir with other drugs have not been conducted.
Information regarding the presence of undesirable interactions with antipyretics, mucolytics, and local vasoconstrictors in clinical research conditions has not been identified.

Antiviral agent.
Specifically suppresses in vitro influenza viruses A and B (Influenzavirus A, B), including highly pathogenic subtypes A(H1N1) pdm09 and A(H5N1), as well as other viruses that cause acute respiratory viral infections (ARVI) (coronavirus associated with severe acute respiratory syndrome (SARS), rhinovirus, adenovirus, respiratory syncytial virus (Pneumovirus), and parainfluenza virus (Paramyxovirus)).
By its antiviral mechanism, it belongs to fusion inhibitors, interacting with the virus's hemagglutinin and preventing the fusion of the virus's lipid envelope with cell membranes.
Exhibits moderate immunomodulatory effects, increasing the body's resistance to viral infections. Has interferon-inducing activity - in studies on mice, interferon induction was noted as early as 16 hours, with high levels of interferons maintained in the blood for up to 48 hours after administration. Stimulates cellular and humoral immune responses: increases the number of lymphocytes in the blood, especially T-cells (CD3), increases the number of T-helper cells (CD4) without affecting the level of T-suppressor cells (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages, and increases the number of natural killers (NK cells).
Therapeutic efficacy in viral infections is manifested in the reduction of the duration and severity of the disease and its main symptoms, as well as in the decrease in the frequency of complications associated with viral infections and exacerbations of chronic bacterial diseases.
In the treatment of influenza or ARVI in adult patients, clinical studies have shown that the effect of umifenovir in adults is most pronounced in the acute phase of the disease, manifested by a reduction in the duration of symptom resolution, a decrease in the severity of disease manifestations, and a shortening of the virus elimination period.
Therapy with umifenovir leads to a higher frequency of symptom relief by the third day of therapy compared to placebo. After 60 hours from the start of therapy, the resolution of all symptoms of laboratory-confirmed influenza exceeds the corresponding indicator in the placebo group by more than 5 times. A significant effect of umifenovir on the rate of influenza virus elimination has been established, which is particularly manifested by a decrease in the frequency of viral RNA detection on the fourth day.
It is classified as a low-toxicity drug (LD50>4 g/kg). It does not exert any negative effects on the human body when taken orally at recommended doses.

Rapidly absorbed and distributed throughout organs and tissues. Maximum plasma concentration after administration of 50 mg is reached in 1.2 hours, and after 100 mg in 1.5 hours. Metabolized in the liver. The half-life is 17-21 hours. Approximately 40% is excreted unchanged, primarily in bile (38.9%) and to a lesser extent by the kidneys (0.12%). Within the first 24 hours, 90% of the administered dose is eliminated.

Umifenovir is an antiviral medication that is actively used in the treatment of various acute respiratory viral infections (ARVI), including influenza. The drug has high efficacy and contributes to a faster recovery of the patient. The capsules contain 50 mg of the active substance and are intended for oral administration. The package includes 20 capsules, which provides a complete course of treatment. Umifenovir is recommended to be taken at the first symptoms of ARVI to accelerate recovery and prevent complications. It is important to remember that self-medication can be dangerous to health, so it is advisable to consult a doctor before starting Umifenovir.